Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Panobinostat |
Synonyms | |
Therapy Description |
Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Panobinostat | Farydak | LBH589 | HDAC Inhibitor 41 | Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02717455 | Phase I | Panobinostat | Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma | Active, not recruiting | USA | 0 |
NCT01169636 | Phase Ib/II | Panobinostat Pegfilgrastim Carboplatin + Etoposide + Ifosfamide | Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | Completed | USA | 0 |
NCT04804709 | Phase I | Panobinostat | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) | Active, not recruiting | USA | 0 |
NCT00946647 | Phase II | Panobinostat Azacitidine | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 6 |
NCT04326764 | Phase III | Panobinostat | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | Active, not recruiting | DEU | 1 |
NCT02722941 | Phase II | Panobinostat | Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | Completed | USA | 0 |
NCT01032148 | Phase I | Panobinostat | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT01321346 | Phase I | Cytarabine Panobinostat | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT02032810 | Phase I | Panobinostat Ipilimumab | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | Completed | USA | 0 |
NCT02720510 | Phase II | Panobinostat Bortezomib + Dexamethasone + Lenalidomide | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) | Terminated | USA | 0 |
NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Recruiting | USA | 0 |
NCT02506959 | Phase II | Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma | Active, not recruiting | USA | 0 |
NCT04897880 | Phase II | Panobinostat | A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (NORTH) | Terminated | USA | 2 |
NCT01336842 | Phase I | Cisplatin Panobinostat Pemetrexed Disodium | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | Completed | USA | 0 |